[Effects of exenatide lar in type 2 diabetes mellitus and obesity].
| Autor: | Sierra Poyatos R; Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz-idc salud. Madrid. España.. roberto.sierra@fjd.es., Riobó Serván P; Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz-idc salud. Madrid. España.. roberto.sierra@fjd.es., Vázquez Martínez C; Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz-idc salud. Madrid. España.. roberto.sierra@fjd.es. |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Nutricion hospitalaria [Nutr Hosp] 2014 Oct 24; Vol. 31 (1), pp. 292-8. Date of Electronic Publication: 2014 Oct 24. |
| DOI: | 10.3305/nh.2015.31.1.8283 |
| Abstrakt: | Introduction: GLP-1 analogs have been shown to be an effective treatment of type 2 diabetes mellitus (DM-2) and obesity. Objectives: Evaluate the efficacy of exenatide LAR on weight loss, glycemic control, blood pressure (BP) and lipid profile, in DM-2 and obesity. Material and Methods: Retrospective study of patients treated with exenatide LAR for 6 months. Demographic data (age, gender), anthropometric, fasting glucose, glycated hemoglobin (HbA1c), blood pressure and lipid profile were collected at baseline and at 6 months after treatment. We performed a logistic regression analysis to assess possible predictors of efficacy. Results: 30 patients (17 male, mean age: 61.7 ± 9.5 years old) with DM-2 of 9.7 ± 6.2 years of evolution. HbA1c was reduced by 1.3% (95%CI 1.04-1.57; p <0.001), weight by 2.8 kg (95%CI 1.67-3.96, p <0.001) and BMI by 1.9 kg/m2 (95%CI 1,08-2,93; p <0,001). Total cholesterol decreased by 26.9 mg/dl (95%CI 9.23-38.8, p = 0.003), LDL cholesterol by 21.2 mg/dl (95% CI 7.56-34.9, p = 0.02) and triglycerides by 53.9 mg/dl (95%CI 46.4-77.1 mg/dl, p = 0.004). No statistically significant changes in blood pressure and HDL cholesterol were observed. 53.3% of patients got an HbA1c <7%, 66.6% lost weight, and 43.3% simultaneously achieved both of them. Neither of the studied variables was confirmed as a predictor of treatment response. Regarding side effects, 53.3% reported gastrointestinal discomfort (nausea) and 26.6% reported subcutaneous nodules of spontaneous resolution. Conclusions: Treatment with exenatide LA, in obesity and DM-2, has shown beneficial effect on lipid weight, BMI, glycemic control and lipid profile, despite the long duration of diabetes in our patients. (Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|